Monte Rosa Therapeutics
GLUE
69 hedge funds and large institutions have $310M invested in Monte Rosa Therapeutics in 2023 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 22 increasing their positions, 20 reducing their positions, and 7 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
43% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 7
10% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 20
5% more funds holding
Funds holding: 66 → 69 (+3)
1% less capital invested
Capital invested by funds: $314M → $310M (-$3.96M)
4.62% less ownership
Funds ownership: 85.19% → 80.57% (-4.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$2.61M |
| 2 |
ECM
ExodusPoint Capital Management
New York
|
+$1.82M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.42M |
| 4 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$664K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$259K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
-$9.24M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$3.89M |
| 3 |
Millennium Management
New York
|
-$1.92M |
| 4 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$1.51M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$1.42M |
GLUE Hedge Fund Activity: Q1 2023 in Review
69 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Monte Rosa Therapeutics (GLUE) for Q1 2023, worth a combined $310M — down 1.3% from $314M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new GLUE positions and 7 closed out — a net gain of 3 holders — while 22 added to existing stakes and 20 trimmed.
The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $2.61M. The largest seller was RTW Investments, exiting entirely with an estimated $9.24M sold.
- 69 institutional investors held Monte Rosa Therapeutics (GLUE) as of Q1 2023, up from 66 in Q4 2022.
- Funds reported $310M of Monte Rosa Therapeutics stock for Q1 2023, down 1.3% quarter-over-quarter.
- 10 funds opened new Monte Rosa Therapeutics positions in Q1 2023 and 7 closed out, a net change of +3 holders.
- The largest Monte Rosa Therapeutics buyer in Q1 2023 was Baker Bros. Advisors, an estimated $2.61M added.
- The largest Monte Rosa Therapeutics seller in Q1 2023 was RTW Investments, an estimated $9.24M sold.
Based on aggregated 13F filings for Q1 2023.